Quantcast
Last updated on April 18, 2014 at 17:24 EDT

Latest Actinium Pharmaceuticals Inc. Stories

2013-11-12 08:34:18

NEW YORK, Nov. 12, 2013 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (OTCQB: ATNM.OB) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced the appointment of Richard I. Steinhart to its board of directors (Board). The Board also named Mr. Steinhart as Chairman of the Board's Audit Committee and a member of the Board's Compensation Committee. The Company's Chief...

2013-10-31 08:32:19

Management will discuss pivotal trial plans for its drug candidate Iomab(TM)-B and its potential as a new treatment paradigm for certain blood cancers NEW YORK, Oct. 31, 2013 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (OTCQB: ATNM.OB) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, will host a general corporate update and Virtual Roadshow to discuss the current plans...

2013-10-15 08:30:18

Panel of Experts to Discuss Potential of Actinium's Iomab-B Product to Revolutionize Field of Bone Marrow Transplant NEW YORK, Oct. 15, 2013 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (OTCQB: ATNM.OB) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, is hosting an online webinar today at 11:00 AM EDT to discuss current progress with Iomab(TM)-B. Iomab(TM)-B has completed a...

2013-10-03 16:23:27

Panel of Luminaries to Discuss the Potential of Iomab-B to Revolutionize and Expand Bone Marrow Transplants NEW YORK, Oct. 3, 2013 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (OTCQB: ATNM) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that it will be hosting an online webinar on October 15, 2013, at 11:00 AM EDT to discuss current progress with Iomab(TM)-B....

2013-09-18 08:28:27

NEW YORK, Sept. 18, 2013 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (OTCQB: ATNM.OB) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced the appointment of Corey Sohmer to the position of Vice President of Finance and Business Development. Mr. Sohmer will be responsible for directing Actinium's accounting, finance and investor relations functions as well as...

2013-09-16 08:27:43

NEW YORK, Sept. 16, 2013 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (OTCQB: ATNM.OB) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced the appointment of Kaushik J. Dave, Ph.D., MBA., to the position of President and Chief Executive Officer effective September 16, 2013. Dr. Dave also joined the Board of Directors of Actinium. Dr. Dave has nearly 25 years of...

2013-07-09 08:27:58

Actinium's lead drug candidate and technology platforms were discussed in a presentation at the IAEA technical meeting in Vienna, Austria NEW YORK, July 9, 2013 /PRNewswire/ -- Actinium Pharmaceuticals Inc. (OTCQB: ATNM), a biopharmaceutical company that develops innovative targeted payload immunotherapeutics for treatment of advanced cancers, announced that the Actinium Pharmaceuticals' clinical programs and platform technology were presented in Vienna, Austria, at a technical...

2013-06-07 08:24:31

Actinium Pharmaceuticals receives US $3,457,087 in proceeds from the exercise of 2,095,204 A-warrants NEW YORK, June 7,­­­­ 2013 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (OTCQB: ATNM) announced today the recent issuance of 2,095,204 of its shares of common stock pursuant to the exercise of A-Warrants originally issued in connection with a private placement that closed in January 2013. The warrants were exercised at US$ 1.65 per share, resulting in gross...

2013-06-05 08:28:09

Targeted Alpha Therapy gains traction with three ongoing clinical alpha trials to be presented at the TAT Symposium in Oak Ridge, TN June 4 - 6, 2013 NEW YORK, June 5, 2013 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (OTCBB: ATNM), a biopharmaceutical company that develops innovative targeted payload immunotherapeutics for treatment of advanced cancers, announced the timing for a presentation devoted to its Acute Myeloid Leukemia clinical programs. The presentation is formally...

2013-05-16 12:31:09

Actinium's lead drug candidate and technology platforms will be discussed in presentations at the TAT Symposium in Oak Ridge, TN June 4 - 6, 2013 NEW YORK, May 16, 2013 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (OTCBB: ATNM), a biopharmaceutical company that develops innovative targeted payload immunotherapeutics for treatment of advanced cancers, announced that the official program of TAT: Target Alpha Therapy (TAT) international symposium will feature a presentation devoted to...